Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taladegib - Endeavor BioMedicines

Next Previous
Drug Profile

Taladegib - Endeavor BioMedicines

Alternative Names: ENV 101; ENV-IPF-101; ENV-ONC-101; LY-2940680

Latest Information Update: 16 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Endeavor BioMedicines; Ignyta
  • Class Antifibrotics; Antineoplastics; Benzamides; Fluorobenzenes; Phthalazines; Piperidines; Pyrazoles; Small molecules
  • Mechanism of Action Patched-1 receptor antagonists; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Idiopathic pulmonary fibrosis; Solid tumours
  • Discontinued Adenocarcinoma; Basal cell cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 15 May 2026 Pharmacodynamics data from a preclinical trial in Idiopathic pulmonary fibrosis presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
  • 28 Apr 2026 Endeavor Biomedicines initiates enrolment in a phase I trial for Idiopathic Pulmonary Fibrosis (In volunteers) in Australia (PO, Tablet) (NCT07454291)
  • 06 Mar 2026 Endeavor Biomedicines plans a phase I trial for Idiopathic Pulmonary Fibrosis (In volunteers) in Australia (PO, Tablet) in March 2026 (NCT07454291)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top